Clinical trial · Observational
Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is aimed at all adult patients diagnosed with advanced thyroid carcinomas and well-differentiated thyroid carcinomas (DTC) iodine-refractory, well-differentiated iodine-refractory thyroid (RAI-R DTC) metastatic carcinomas that are candidates for systemic therapy. By simple blood sampling and analysis on peripheral blood of circulating DNA (ccf-DNA), circulating RNA (ccf-RNA), and counting and analysis of circulating tumor cells through the use of liquid biopsy, molecular profiling corresponding to those obtained by genomic sequencing on tumor tissue can be arrived at, depending on optimal therapeutic choices
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Carcinoma | Thyroid Gland Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with advanced thyroid carcinomas
- description
- Adults patients with advanced thyroid carcinomas will be enrolled.
- interventionNames
- Diagnostic Test: 4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA
Primary outcomes (1)
- measure
- Genomic alterations
- timeFrame
- Before the start of pharmacologic treatment and after 30 days and 3, 6 and 24 months after the start of treatment
- description
- Presence of BRAF mutations, RAS mutations, RET mutations, rearrangements of NTRK, RET, ALK, etc. in ccf-DNA, ccf-RNA and Circulating Tumour Cells (CTCs)
Secondary outcomes (6)
- measure
- Early metabolic response rate
- timeFrame
- 30 days from the start of pharmacologic treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed written informed consent, * Adult (≥18 years) male or female patients * Histologic diagnosis of advanced thyroid carcinoma confirmed at centralized review, * well-differentiated thyroid carcinomas, medullary thyroid carcinomas, anaplastic thyroid carcinomas, advanced, candidates for initiation of systemic medical therapy, * Availability of biomolecular profiling performed by multigenic NGS panel on tumor tissue, * Measurable disease by conventional imaging adopted in clinical practice (total body CT with mdc, CT-PET with FDG or F-DOPA). Exclusion Criteria: * Patients already receiving previous lines of systemic therapy, * Patients not eligible for systemic therapy.
References
Publications (0)
Data not yet available